|
CDER News Items 2009
• January 16. Follow-up tFDA Public Health Advisory Potential Hazards of Skin Products Containing Numbing Ingredients for Relieving Pain from Mammography and Other Medical Tests and Conditionso the March 27, 2008, Communication about the Ongoing Safety Review of Montelukast (Singulair) Information
• January 13. Follow-up to the March 27, 2008, Communication about the Ongoing Safety Review of Montelukast (Singulair) Information
• January 8. Follow-up to the January 25, 2008 Early Communication about an Ongoing Data Review for Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor). Information
• January 5. On Dec. 31, 2008, Celgene issued a Dear Healthcare Professional letter describing a controlled clinical study suggesting that Innohep may increase the risk for death, compared to unfractionated heparin when used to treat elderly patients with renal insufficiency. MedWatch Safety Alert
News Items 2008
News Items 2007
News Items 2006
News Items 2005
News Items 2004
News Items 2003
News Items 2002
Back to Top
Back to CDER Home
 PDF requires the free
Adobe Acrobat Reader
Date created: January 5, 2009 |
